Close

Bone Therapeutics to build new manufacturing facility in Belgium

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Fluid Path Integrity: Ensuring Purity in Biomanufacturing

In the high-stakes arena of biomanufacturing, where tiny contaminants...

GMP Fluid Handling: Regulatory Compliance Explained

Fluid Handling in GMP Manufacturing: The Essence of Regulatory...

Single-Use Technologies in Biopharma Transform Manufacturing

The biopharmaceutical sector is being revolutionized by the demand...

Advances in Aseptic fluid transfer solutions

Sterility and Cross-Contamination: The Cornerstones of Modern Biopharma Manufacturing Biopharmaceutical...

Biopharmaceutical company Bone Therapeutics has announced that it has made a €10m investment in Skeletal Cell Therapy Support (SCTS) to build a new manufacturing facility at Gosselies Scientific Park near Brussels in Belgium.

The new manufacturing facility, which is funded through equity and loans basis from ING and BNP Paribas Fortis and subsidies from the Walloon Region, will produce its unique bone cell therapy products on a commercial scale.

The new facility will manufacture Bone Therapeutics’s major product PREOB, an autologous bone cell therapy product currently in Phase III clinical trials for the treatment of osteonecrosis, under GMP conditions.

The facility, which is expected to be completed by 2015, will initially include six class B production cells across 1.950m2 space and will be able to produce up to 5.000 batches per annum at full capacity.

In addition to this, the facility will also accommodate a 1.300m2 space for a quality control and research activities.

After completion of the new facility, Bone Therapeutics will be headquartered at the factory. Bone Therapeutics chief executive officer Enrico Bastianelli said the company is collaborating with local venture to build a dedicated cell therapy industrial manufacturing facility in Wallonia.

“Securing access to these state of the art facilities is in line with Bone Therapeutics’ strategy to become a successful commercial stage company and to support the potential commercialization of our lead product PREOB®, which is now ready for manufacturing and scale up,”Bastianelli added.

 

Latest stories